Phaseline

Companies › Geneos Therapeutics

Geneos Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GNOS-PV02
personalized neoantigen DNA vaccine
–Phase 2HCCNov 2028
INO-9012
plasmid encoded interleukin-12 (IL-12) vaccine adjuvant
IL12Phase 2HCCNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04251117GNOS-PV02Phase 1HCCOncologyNov 2028
NCT04251117INO-9012Phase 1HCCOncologyNov 2028
NCT07722741GNOS-PV02Phase 2HCCOncologySep 2029
NCT07722741INO-9012Phase 2HCCOncologySep 2029

Targets

IL12 (1)

Companies with the same targets

Strand Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix

Companies built like this

Newish Technology (Beijing) BrainChild Bio TVAX Biomedical Lukas Biomedical RhoVac APS

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.